Interventions: CagriSema (Cagrilintide B and Semaglutide I), placebo Primary Outcome Measure: Relative change in body weight Time Frame: From baseline (week 0) to week 80 Study Details Source VK2735 for Weight Management Phase 3 (VANQUISH 1) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI 30 kg/m2) or overweight (BMI 27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes
The clinical landscape is shifting dramatically
Get the blood test first
These three major areas have shown a reduction in wrinkles and inflammation, an increase in skin firmness, and an overall more even tone
Peptide degradation and plasma stability chapter
Future research directions may include: Investigating the safety and efficacy of DSIP in human clinical trials, particularly in the context of sleep disorders, anxiety, and stress-related conditions because of promising effects on emotional and psychological responses